Case description: 32-month-old boy, IgG positive for SARS-CoV-2, presented to the emergency department with dermatologic lesions. Clinical findings: Four days before admission, he presented skin eruptions with redness and pruritus on hands and feet. Generalized papular erythema was evidenced, upper extremities with diffuse erythematosquamous plaques, palmoplantar keratoderma, so he was evaluated by a dermatologist who diagnosed pityriasis rubra pilaris. Treatment and outcome: rehydrating cream, cetirizine 0.5 mg/kg/day every two days, and prednisolone 2 mg/kg/day in the morning. He was discharged after 14 days, the patient presented clinical improvement, but the erythematous lesion persisted on the trunk and extremities. In the evaluation, after three months, the patient did not show the described lesions, evidencing an improvement and clinical resolution of the dermatological problems. Clinical relevance: We report a patient with pityriasis rubra piloris associated with a post-infection by SARS-CoV-2 that had not been described before.

La enfermedad por el nuevo coronavirus (COVID-19) causada por el virus SARS-CoV-2, fue detectada por primera vez durante la epidemia del distrito de Wuhan en la provincia de Hubei en China en diciembre de 2019. Desde entonces ha tenido una rápida y exitosa expansión en países asiáticos y europeos, debido principalmente a la demora en la toma de decisiones drásticas para contenerlo. Y es que a pesar de que es la primera vez con que disponemos con tanta  información en tiempo real de una Pandemia, al parecer el exceso de la misma ha generado diversas interpretaciones, lo que no ha  permitido un análisis oportuno de este problema en los países más afectados. Por ello, y ante el surgimiento de casos en Latinoamérica se debe tomar como experiencia lo sucedido en estos continentes y reconocer los desafíos a los cuales se enfrenta esta región ante la inminente expansión de este virus en esta región.

No abstract

Introduction: Toxoplasmosis is a zoonosis caused by Toxoplasma gondii. This study investigated the prevalence and factors associated with toxoplasmosis among pregnant women. Methods: We followed an analytical observational study. From July 2016 to June 2017, 218 pregnant women were selected. The infection was detected through serological dosage of anti-T.gondii Immunoglobulin(Ig) M and IgG antibodies. Results: The seroprevalence was 35.8%; the factors associated with infection were consumption of non-drinking water, residence in an urban area, and threatened abortion during the current pregnancy. Conclusions: The seroprevalence of toxoplasmosis among pregnant women is high. The risk factors are dependent on environmental determinants.

No abstract